On the REPROCELL blog
Latest
AI-Designed CRISPR Enables Hypoimmune iPSC Engineering for Off-the-Shelf Cell Therapy
REPROCELL's StemEdit platform enables the creation of hypoimmune iPSCs for scalable off-the-shelf cell therapies, reducing immune rejection and enhancing patient access.
04 June 2026
What Are Off-Target Effects in Cellular Gene Editing? Risks, Detection, and Solutions
Explore off-target effects in gene editing, from CRISPR risks and AI-driven detection to genomic safety in iPSC therapies.
20 May 2026
What to Look for in a Global Central Lab Partner for Clinical Trials
Selecting the right global central lab partner is crucial for clinical trial success, impacting data quality, logistics, and regulatory compliance.
14 May 2026
The Resurgence of New Approach Methodologies (NAMs) in Drug Discovery and Safety Assessment
Explore how New Approach Methodologies are revolutionizing drug discovery and safety assessment by enhancing human-relevant research and reducing reliance on animal testing.
30 April 2026
Upcoming Events
Conferences we will be attending, and webinars hosted by us.
Corporate News
02 June 2026
01 June 2026
REPROCELL USA Inaugurates GMP-Compliant Cell Culture Facility
09 April 2026
Investor Relations News
- May 27, 2026
-
Notice Concerning Grant Awarded to Consolidated Subsidiary (REPROCELL USA Inc.)
May 22, 2026 - Apr 02, 2026


%20vial.jpg)








